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Abstract
Background: Conflicting findings and the analysis of unpublished and retracted data have led to controversy on
the safety of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in people with COVID-19
infection. This meta-analysis examined the association of prescription of angiotensin-converting enzyme inhibitors
(ACEI) and angiotensin receptor blockers (ARB) with the outcome from COVID-19.
Methods: A systematic search was conducted to find published studies that reported the outcome of COVID-19 in
relation to prescription of ACEI or ARB. Two authors (MF and AD) independently screened and extracted data and
assessed study quality and strength of association using standardised tools. The endpoints for the meta-analyses
were severe or critical disease outcome and mortality based on standardised criteria.
Results: Twenty-six studies including 8389 people prescribed ACEI or ARB and 20,989 people not prescribed these
medications were included. The quality of studies varied, and the overall strength of association was poor with a
high risk of confounding bias. Patients prescribed ACEI or ARB had a greater prevalence of risk factors. Meta-analysis
found an association between prescription of ACEI or ARB with severe or critical disease outcome (risk ratio, RR,
1.23, 95% confidence interval, CI, 1.06 to 1.42, p = 0.006, I2 = 88%) but this association was lost in sensitivity
analyses. There was no association between ACEI or ARB prescription and mortality (RR 1.18, 95% CI 0.92 to 1.50, p
= 0.19, I2 = 82%).
Conclusions: This meta-analysis suggests that people prescribed ACEI or ARB more commonly had severe or
critical disease outcome, but not mortality, in published cohorts of patients diagnosed with COVID-19. This finding
is most likely due to a greater prevalence of risk factors in these patients rather than due to exposure to
angiotensin pathway inhibitors.
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Introduction
The SARS-CoV-2 virus, which is responsible for
COVID-19, is believed to bind to host cells via
angiotensin-converting enzyme 2 (ACE2) [1]. ACE2 ex-
pression in some experimental models is altered (both
up and downregulation has been reported) by the com-
monly used antihypertensive drugs angiotensin-
converting enzyme inhibitors (ACEI) and angiotensin re-
ceptor blockers (ARB) [2, 3]. Meta-analyses suggest that
people with a history of hypertension have poor out-
comes from COVID-19 [4, 5] that could conceivably be
due to the prescription of ACEI or ARBs [6].
A number of previous meta-analyses and reviews have
explored the association of ACEI and ARB exposure
with the outcome of COVID-19 but the findings have
been inconsistent [7–11]. Some have reported no signifi-
cant association between ACEI or ARB prescription and
outcome [7–9], whilst others have found reduced mor-
tality in patients prescribed these medications [10, 11].
These previous reviews have had a number of deficien-
cies, including failure to assess the quality of the in-
cluded studies and limited examination of the strength
of associations identified. Previous analyses have also in-
cluded unpublished and later retracted studies, leading
to concerns about the validity of findings [12]. Further-
more, many new relevant studies have since been pub-
lished. The aim of this systematic review was to provide
an up-to-date and robust assessment of the association




This systematic review and meta-analysis was conducted
according to the Preferred Reporting Items for System-
atic reviews and Meta-Analyses (PRISMA) statement
and the Meta-analysis Of Observational Studies in Epi-
demiology (MOOSE) reporting standards [13, 14]. The
final search for original studies was performed on the
19th of June 2020 using multiple databases [MEDLINE
via OvidSP, and PubMed]. The search string is shown in
S1: Text Box 1. Reference lists of identified publications
were hand searched to identify other potentially eligible
studies.
Inclusion of studies
Prospective or retrospective cohort and case-control
studies reporting the outcome from COVID-19 in rela-
tion to ACEI and/or ARB prescription were eligible for
inclusion. Animal studies, reviews and editorials were
excluded. Only articles published in English were in-
cluded and there were no restrictions on publication
date. Titles and abstracts of publications identified were
screened by two authors (MF, AD) to find studies
meeting the eligibility criteria. The full texts of publica-
tions that appeared relevant were reviewed by both au-
thors and a decision regarding inclusion made by
consensus with the third author (JG).
Definitions of COVID-19, risks factors, drug exposure and
outcomes
COVID-19 diagnosis was based on World Health Or-
ganisation (WHO) interim laboratory testing for
COVID-19 criteria [15]. Hypertension, diabetes, ischae-
mic heart disease (IHD), chronic obstructive pulmonary
disease (COPD), congestive cardiac failure (CCF) and
chronic kidney disease (CKD) were defined by prior
diagnosis on electronic medical records as per the inter-
national statistical classification of diseases and related
health problems version 10 (ICD-10) [16]. Medications,
including ACEI or ARB, were based on record of drug
prescription at the time of hospital admission. The pri-
mary outcomes were severe or critical disease and mor-
tality according to a report of the WHO-China Joint
Mission on COVID-19 [17]. Severe disease was defined
as the presence of tachypnoea (≥ 30 breaths/min), oxy-
gen saturation ≤ 93% at rest, arterial oxygen tension
(PaO2) over inspiratory oxygen fraction (FIO2) PaO2/
FiO2 ratio of < 300 mmHg, or a clinical diagnosis of
ARDS or prolonged hospitalisation (≥ 10 days) [17].
Critical disease was defined as people with respiratory
failure requiring mechanical ventilation, shock or other
organ failure that requires intensive care. A severe or
critical disease outcome of COVID-19 was defined to in-
clude both severe and critical disease definitions or
death. Mortality was defined as any in-hospital death
where COVID-19 was thought to have contributed, as
per the WHO guidelines [18]. Exposure to ACEI and/or
ARB prescription was defined as a prescription of these
medication classes preceding a diagnosis of COVID-19
irrespective of continued medication use at the time of
hospitalisation.
Data extraction
Data extracted included the number of primary outcome
events in relation to prescription of ACEI/ARB (expos-
ure), the country where the study took place, study de-
sign, sample size, age, sex, hypertension, prescribed anti-
hypertensive medications, comorbidities, systolic and
diastolic blood pressure (mmHg) and biochemical data
at admission [potassium (mmol/l), creatinine (μ mol/L),
estimated glomerular filtrated rate (ml/min per 1.73 m2)
and C-reactive protein (CRP) (mg/L)]. All data were in-
dependently extracted by two authors (MF, AD) using a
standardised template and inconsistencies were resolved
through discussion with a third author (JG). The defini-
tions used by studies are reported in S1: Supp Table 1.
To obtain missing data or clarify any discrepancies,
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corresponding authors of all studies were contacted via
email, of whom 13 responded. Five authors replied with
additional data [19–23], and eight authors responded
but could not provide additional data [21, 24–30]. A
number of publications reported potentially overlapping
data through utilising the same hospitals during the
same time period [11, 19, 31–33] and therefore sensitiv-
ity analyses were performed whilst excluding and includ-
ing these studies.
Quality assessment
Two assessors (MF, AD) independently evaluated the
quality of studies using a modified version of the Risk Of
Bias In Non-randomised Studies of Interventions tool
[34]. The items assessed included participant selection
bias, information bias of study outcomes, definition of
exposure of ACEI/ARB prescription, reporting bias due
to missing data and the risk of confounding [34]. Any
inconsistencies were resolved through discussion until
consensus was reached. Each item (10 questions) was
assessed as yes, no or not reported. A “yes” was scored
as 1 and a “no” or “not reported” as 0. The scoring of all
items was then summed and presented as a percentage
of the total possible score of 10. The final agreed and in-
dividual quality scores and degree of agreement were
reported.
Evaluating the strength of association
Two assessors (MF, AD) independently evaluated the
strength of association between ACEI/ARB prescription
and COVID-19 outcome using relevant components of
the Sir Bradford Hill Criteria: dose response relationship,
temporal sequence and protopathic bias (timing and
duration of ACEI/ARB prescription), biological plausibil-
ity and specificity of exposure and outcome [35].
Statistical analysis
The main meta-analysis examined the association be-
tween exposure to ACEI or ARBs (as a combined group)
and outcome from COVID-19. Subgroup analyses were
performed to examine the associations of ACEI prescrip-
tion alone or ARB prescription alone with outcome.
Leave-one-out sensitivity analyses were performed to as-
sess the contribution of each study to the pooled esti-
mates by excluding individual studies one at a time and
recalculating the pooled estimates [36]. Sensitivity ana-
lyses were also performed focusing on people with a his-
tory of hypertension alone, excluding potential
overlapping cohorts and focusing on studies from indi-
vidual continents (Asia, USA or Europe) and high-
quality investigations (defined as quality assessment
scores ≥ 90%). All meta-analyses were performed using
Mantel-Haenszel’s statistical method and random effect
models anticipating substantial heterogeneity [37]. The
results were reported as risk ratios (RR) and 95% confi-
dence intervals (CI). All statistical tests were two-sided
and a p value < 0.05 was considered significant. Hetero-
geneity was assessed using the I2 statistic values (inter-
preted as 0 to 49%: low, 50 to 74%: moderate and 75 to
100%: high) [38]. Publication bias was assessed by funnel
plots comparing the summary estimate of each study
and its precision (1/standard error) [36]. All analyses
were conducted using Review Manager 5 (RevMan 5)




Twenty-six studies from 664 identified articles met the eli-
gibility criteria and were included (Fig. 1) [19–33, 39–49].
Cohort characteristics
Thirteen studies were from China, five from Italy, three
from the USA and one each from Denmark, Spain,
Korea, the UK and France. A total of 29,378 out of
44,454 people diagnosed with COVID-19 comprising
8389 people who were prescribed ACEI/ARB and 20,989
people not prescribed ACEI/ARB were included in the
meta-analysis (S1: Supp Table 2-3). The characteristics
of participants stratified by the prescription of ACEI/
ARB are reported in Table 1. The weighted average age
of people prescribed ACEI/ARB was higher than the
control group (70 years vs. 56 years). Participants in the
ACEI/ARB group were more likely to be male (58% vs.
50%) and have hypertension (92% vs. 39%), diabetes
(30% vs. 11%), IHD (21% vs. 7%), CCF (14% vs. 3%).
CKD (10% vs. 3%) and COPD (12% vs. 7%) than those
not prescribed these drugs. Additional data including
blood pressure, C-reactive protein, incidence of severe
or critical disease and mortality according to ACEI/ARB
and differences in the inpatient use of steroids and anti-
viral medications stratified by groups is reported in S1:
Supp Table 2-6.
Study quality and strength of association
Quality scores from the two assessors are reported in
S1: Supp Table 7. There was agreement on 233 of the
260 (90%) assessments made. The final quality assess-
ments reached after a consensus meeting are reported in
Table 2. The overall quality of studies ranged from 20%
(low) to 90% (high). All but eight articles reported on
participant selection bias [19, 23, 25, 31, 33, 41, 45, 46].
All studies except three [22, 27, 44] reported the method
of COVID-19 diagnosis (S1: Supp Table 1), but two
studies [31, 46] included people with computed
tomography-based diagnoses and two studies did not
confirm all diagnoses with PCR [25, 31]. All but six stud-
ies provided outcome definitions for COVID-19 related
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mortality [20, 21, 28, 29, 43, 48]. Thirteen studies pro-
vided a clear or surrogate definition for severity [19, 21,
24, 25, 28, 29, 32, 33, 39, 40, 43, 48, 49]. Analyses adjust-
ing for major confounders were reported in twelve stud-
ies [21–23, 25, 26, 28, 29, 31, 40, 47–49] and seven
studies reported follow-up until all patients were either
deceased or discharged [19, 20, 29, 31, 39, 46, 49].
Twelve studies contained more than 10% missing data
[20, 21, 23–25, 30–32, 41, 43, 46, 49]. Twelve studies re-
ported confidence precision estimate of association of
ACEI/ARB with outcomes [21–29, 40, 47, 49]. One
study included 17 people prescribed ACEI/ARB in the
control group [40]. The overall strength of association
between ACEI/ARB and outcomes was low (Table 3).
None of the studies investigated the relationships be-
tween ACEI/ARB dose and outcome and only five stud-
ies reported whether ACEI/ARBs were continued during
admission [19, 27, 40, 41, 46]. Only one study reported
the association of continuation or discontinuation of
medication during hospitalisation and outcome [27].
Biological plausibility and specificity of exposure and
outcome were poorly evaluated in most studies and
there was a high risk of confounding.
Association of ACEI/ARB prescription with severe or
critical disease outcome
The meta-analysis incorporated 1930 severe or critical
disease outcomes in 8389 people prescribed ACEI/ARB
vs. 3822 severe or critical disease outcomes in 20,989
people not prescribed these medications from all 26
studies. The risk of severe or critical disease outcome
was greater in people prescribed ACEI or ARB than
those who were not (RR 1.23, 95% CI 1.06, 1.42, Z =
2.73, p = 0.006). There was a high degree of heterogen-
eity (I2 = 88%) (Fig. 2). Sub-group analyses found that
people prescribed ACEI (RR 1.33, 95% CI 1.08, 1.63, Z =
2.68, p = 0.007) or ARB (RR 1.28, 95% CI 1.07, 1.52, Z =
2.68, p = 0.007) were at higher risk of severe or critical
disease outcomes than those who were not prescribed
these drugs (S2: Supp Fig 1-2). Amongst people with a
history of hypertension, there was no association be-
tween prescription of these medications and severe or
Fig. 1 PRISMA flow diagram detailing the search results on the 19th June 2020
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Table 2 Quality of included studies based on standardised criterion
Legend: Table reports the final agreed quality of studies reported as a percentage (out of ten questions). The full questions are reported in Supplement and the
scoring method given in “Material and methods.” The total number of studies meeting each criterion is reported in the final column (out of 25 studies). The green
and red coloured cells represent the criteria which were and were not met in each study, respectively
Table 3 Strength of association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker prescription and
COVID-19 outcome based on standardised criteria
Legend: Table reports on the assessment of strength of association based on the Sir Bradford Hill criteria.37 The green and red coloured cells represent the criteria
which were and were not met in each study, respectively. Use of inflammatory markers required the reporting of at least one inflammatory marker in relation to
ACEI/ARB prescription. An effect on blood pressure required the reporting of systolic and/or diastolic blood pressure in relation to ACEI/ARB prescription. Although
Reynolds et al. reported data regarding continuation of medication, no data on outcomes were reported
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critical disease outcomes (S2: Supp Fig 3). Sensitivity
analyses showed that when the analyses were restricted
to people recruited from individual continents or high-
quality studies, there was no significant association be-
tween ACEI/ARB prescription (or ACEI alone or ARB
alone) and severe or critical disease outcomes (S1: Supp
Table 9-11). The funnel plots were asymmetrical (S2:
Supp Fig 4-7).
Association of ACEI/ARB prescription with COVID-19-
related mortality
There were 692 deaths in 3648 people prescribed ACEI/
ARB vs. 1375 deaths in 14,693 people not prescribed
these medications reported from 21 studies. Meta-
analysis showed no statistically significant association
between ACEI/ARB prescription and mortality (RR 1.18,
95% CI 0.92, 1.50, Z = 1.31, p = 0.19). There was a high
degree of heterogeneity (I2 = 82%) (Fig. 3). Sub-group
analyses found no significant associations between pre-
scription of ACEI or ARB alone and mortality (S2: Supp
Fig 8-9). A sensitivity analysis focused on people with a
history of hypertension alone incorporated 246 deaths in
1164 people prescribed ACEI/ARB vs. 513 deaths in
2639 people not prescribed these medications from 11
studies. This found a lower risk of death in people pre-
scribed ACEI or ARB (RR 0.72, 95% CI 0.52, 0.99, Z =
2.03, p = 0.04) with a moderate degree of heterogeneity
(I2 = 58%) (Fig. 4). Sensitivity analyses suggested that
findings for the main analysis and class-specific analyses
were not dependent on the inclusion of any individual
studies and were similar when restricted to people re-
cruited from individual continents or high-quality
Fig. 2 Forest plot of COVID-19 severity and association with prescription of ACEI/ARB
Fig. 3 Forest plot of COVID-19 mortality and association with prescription of ACEI/ARB
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studies (S1: Supp Tables 11-13). The finding of the
analysis restricted to people with hypertension was
largely dependent on the inclusion of two studies (S1:
Supp Table 13). The funnel plots were asymmetrical
(S2: Supp Fig 4-7).
Discussion
Ideally, choices about drug prescription should be based
on data from randomised controlled trials; however,
such studies are not easy to perform during a pandemic.
To our knowledge, this is one of the largest and only
meta-analysis to pool data exclusively from published
observational studies to examine whether an association
exists between ACEI or ARB prescription and COVID-
19 outcome. The main meta-analyses showed that
people prescribed ACEI/ARB had a higher risk of severe
or critical disease outcomes. Observational studies are
subject to biases that must be considered during inter-
pretation. It is therefore important to highlight that
people prescribed ACEI/ARB were older and more likely
to be male and had higher prevalence of a number of
co-morbidities, including hypertension, diabetes, IHD,
CCF, CKD and COPD, that have been associated with
worse outcome from COVID-19 [50–53]. Furthermore,
the association between ACEI/ARB and severe or critical
disease outcomes was not robust, being lost in sensitivity
analyses restricted to people with hypertension, those re-
cruited from individual continents or high-quality stud-
ies. There was also no association between drug
prescription and mortality in most of the analyses except
the one restricted to people with hypertension in which
there was a 28% lower mortality in people prescribed ei-
ther ACEIs or ARBs. The latter finding was not however
robust in sensitivity analyses. Overall, these findings sug-
gest that there is no robust published observational data
that ACEI/ARB prescription is associated with worse or
better outcome from COVID-19. Thus, the findings sug-
gest no evidence to stop or start these medications in
people admitted to hospital with COVID-19.
Since our search was conducted, there have been other
meta-analyses published examining the relationship be-
tween ACEI/ARB prescription and COVID-19 outcomes
[54–62]. These analyses (amongst others not described
here) differ widely in their total number of included
studies, study type(s) included, patient populations, in-
clusion of retracted studies [56], undertaking of quality
assessment and use of quality assessment outcomes in
interpreting the results and inclusion of pre-print articles
[56, 59–62]. These differences likely contributed to the
conflicting findings between this and similar studies.
Many analyses have found no significant difference in ei-
ther COVID-19 severity or mortality related to ACEI/
ARB prescription [55, 56, 58, 61] whilst others have
found significant reductions either for the whole popula-
tion [54, 57, 62] or in sub-analyses, such as for patients
with hypertension [59, 60]. No studies have found an in-
creased risk of severe disease or mortality from COVID-
19 in relation to ACEI/ARB prescription. Some analyses
also examined the association between ACEI/ARB pre-
scription and the risk of COVID-19 infection, which also
varied depending on the class of agent (significant re-
duction with ACEI but not ARB) [57], and sub-analyses
of the patient population (significant increase but not
when adjusting for patients with hypertension) [58].
The outcomes from COVID-19 found in this study
were likely influenced by treatments received whilst in
the hospital including the use of systemic steroids and
anti-viral medication, but these were poorly reported in
the included studies. At the time of writing, dexametha-
sone is the only medication with a proven reported
Fig. 4 Forest plots of COVID-19 mortality and association with prescription of ACEI/ARB in people with a previous history of hypertension
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mortality benefit in people infected with COVID-19
based on high-quality randomised controlled trial data
[63]. Dexamethasone reduced deaths by one-third in pa-
tients receiving invasive mechanical ventilation com-
pared to standard care [63]. Very few studies included in
the current meta-analysis reported the in-patient treat-
ment differences between people prescribed and not-
prescribed ACEI/ARB, and in the studies that did report
in-patient treatments, several studies reported differ-
ences in the use of supportive therapies including
greater use of corticosteroids during hospital admission
in people prescribed ACEI/ARB [20, 23, 39, 41, 44].
Key elements to any systematic review are evaluations
of study quality and strength of association. Only three
(12%) of the included studies were deemed high quality.
The strength of association between exposure and out-
come in the studies was also limited. Additionally, given
the retrospective design of most studies, selection bias
remains an important problem [31]. Although not ex-
plored in the current meta-analysis, whether the pre-
scription of ACEI/ARB has an association with the
incidence of COVID-19 still remains unclear although a
lack of such association has been reported [64], though
others are conflicting [57, 58].
This meta-analysis had a number of strengths and lim-
itations. Strengths included the systematic approach and
careful examination of the quality and strength of associ-
ation using standardised tools and extensive sensitivity
analyses [13, 35, 65]. It is possible that dual reporting of
data from similar populations may have occurred. Sensi-
tivity analyses were performed to minimise the effect of
this on the overall outcome. Adjustment of analyses for
confounding factors, such as older age, hypertension,
diabetes, IHD and CKD, was not possible, and it is likely
that the association of ACEI/ARB prescription and se-
vere or critical disease outcomes resulted from residual
confounding due to disproportional prevalence of risk
factors in the two groups. We only included studies pub-
lished in English in the search period listed. Lastly, the
impact of protopathic and residual bias due to cessation
or initiation of ACEI/ARB during hospital admission
was not adequately assessed in almost all the included
studies and is an important consideration.
Conclusions
This meta-analysis of published observational studies
suggests that there is no robust published observa-
tional data that ACEI/ARB prescription is associated
with worse or better outcome from COVID-19. Thus,
similar to the recommendations from other studies,
the findings suggest no evidence to stop or start these
drugs in people admitted to the hospital with
COVID-19.
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